 On Friday, ChemoCentryx Inc. NASDAQ:CCXI shares spiked nearly 70 after announcing the Food and Drug Administration FDA had approved avacopan for the treatment of ANCA vasculitis. Avacopan is an orally administered small-molecule C5a receptor antagonist, which selectively blocks the effects of C5a through the C5a receptor. 